e-learning
resources
London 2016
Monday, 05.09.2016
New findings in mucosal immunology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
IL-23 is essential to the development of elastase-induced pulmonary inflammation and emphysema
Utako Fujii (Okahama, Japan), Utako Fujii, Nobuaki Miyahara, Akihiko Taniguchi, Daisuke Morichika, Naohiro Oda, Koichi Waseda, Etsuko Kurimoto, Mikio Kataoka, Akihiko Yoshimura, Arihiko Kanehiro, Mitsune Tanimoto
Source:
International Congress 2016 – New findings in mucosal immunology
Session:
New findings in mucosal immunology
Session type:
Poster Discussion
Number:
1831
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Utako Fujii (Okahama, Japan), Utako Fujii, Nobuaki Miyahara, Akihiko Taniguchi, Daisuke Morichika, Naohiro Oda, Koichi Waseda, Etsuko Kurimoto, Mikio Kataoka, Akihiko Yoshimura, Arihiko Kanehiro, Mitsune Tanimoto. IL-23 is essential to the development of elastase-induced pulmonary inflammation and emphysema. Eur Respir J 2016; 48: Suppl. 60, 1831
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Definition and history of sarcoidosis
Related content which might interest you:
Cigarette smoke induced pulmonary emphysema is attenuated in CCR6 deficient mice
Source: Annual Congress 2006 - Cell biology of asthma and COPD
Year: 2006
Role of CD69 in the pathogenesis of elastase-induced pulmonary inflammation and emphysema
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
Cigarette smoke-induced pulmonary inflammation, but not airway wall remodeling, is attenuated in CCR5 deficient mice
Source: Annual Congress 2007 - The best of airway epithelial cells
Year: 2007
COPD is associated with reduced pulmonary interstitial expression of pentraxin-3
Source: Eur Respir J 2012; 39: 830-838
Year: 2012
Suppressed pulmonary expression of leptin in lipopolysaccharide-induced acute and chronic lung inflammation
Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS)
Year: 2006
The role of chemokines and cytokines in lung fibrosis
Source: Eur Respir Rev 2008; 17: 151-156
Year: 2008
Hyperhomocysteinemia promotes pulmonary emphysema in murine model of COPD
Source: International Congress 2019 – Involvement of the environment and inflammation in pulmonary remodelling
Year: 2019
Airway inflammation in COPD: physiological outcome measures and induced sputum
Source: Eur Respir J 2003; 21: 19S-28S
Year: 2003
Interleukin-17A in the pathogenesis of elastase-induced emphysema in mice
Source: Annual Congress 2012 - Recent progress in mechanisms and diagnostics of COPD and asthma
Year: 2012
Lung function and sputum neutrophil changes in an experimental model of virus-induced COPD exacerbations
Source: Annual Congress 2005 - COPD: role of infection
Year: 2005
Role of IFNg in smoke-induced pulmonary emphysema and cachexia
Source: Eur Respir J 2005; 26: Suppl. 49, 732s
Year: 2005
The novel compound Sul-121 inhibits inflammation in experimental models of chronic obstructive pulmonary disease
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
P2RX4 signalling enhances acute cigarette smoke-induced lung inflammation and chronic lung emphysema development
Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets
Year: 2019
IL-36? – a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease
Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease
Year: 2021
Alveolar remodelling in COPD
Source: Annual Congress 2006 - PG15 - Remodelling and repair in lung disease
Year: 2006
Sirtuin3 reduces acute lung inflammation and emphysematous aggravation in COPD exacerbation mouse model
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Year: 2019
Systemic and airway inflammation and the presence of emphysema in patients with COPD
Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment
Year: 2009
Is lung emphysema in COPD patients reflected by central airways inflammation?
Source: Eur Respir J 2003; 22: Suppl. 45, 207s
Year: 2003
Interleukin-18 production and pulmonary function in COPD
Source: Eur Respir J 2008; 31: 287-297
Year: 2008
LSC - 2019 - Resistive breathing aggravates pulmonary inflammation and emphysema in experimental models of chronic obstructive pulmonary disease
Source: International Congress 2019 – Oxidative stress, hypoxia and microbial exposure in the pathogenesis of pulmonary disease
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept